Pharmaceutical giants had “no legitimate role” in evaluating their products beyond initial development stages and their involvement was “distorting” the debate, BMJ c... Read more
(Extra details were added on July 4 – see bottom of the post). Longstanding investigations into GlaxoSmithKline’s sales, marketing and pricing practices in the US have resulted in the... Read more
It seems we are in the midst of a veritable outbreak of reports raising concerns about conflicts of interest in health and medicine. Guideline developers under scrutiny The BMJ has published... Read more
As recently reported at Croakey, the Australian arm of the pharmaceutical company GlaxoSmithKline (GSK) is moving to be more transparent about how much it pays health care professionals. Tod... Read more
Which doctors and other healthcare professionals are receiving payments from pharmaceutical companies? And how much are they getting? To some extent, people in the US already have access to... Read more
Dr Geoffrey Spurling from the University of Queensland recently reported for Croakey on a systematic review investigating the impact of pharmaceutical promotion. The authors concluded that m... Read more
I know, I know – we’re all too busy, no time to read etc – but here are a few articles from recent times that are worth the effort, if you haven’t spotted them alread... Read more
As mentioned recently, Pfizer is hitting the consumer and medical media in the interests of its combination heart pill, Caduet. Regular readers may remember that earlier this year Michele Ko... Read more
The organisers of a forum on pharmaceutical regulation, to be held in Adelaide on Thursday, are promising a “robust discussion”. I hope there are plans for a podcast as I’... Read more
Professor Garry Jennings, Director of the Baker IDI Heart & Diabetes Institute, has responded to recent Croakey posts raising concerns about his organisation’s close ties with indu... Read more
